Novo Nordisk Investor Relations Material

Novo Nordisk is a Danish global healthcare company focused on treatment of serious chronic conditions. They specialize in developing and manufacturing innovative pharmaceutical products, including insulin, GLP-1 analogs, and other treatments. With a strong commitment to R&D within the field of medical science and through a focus on helping chronically ill patients, Novo Nordisk aims to improve the lives of people living with serious diseases.

Novo Nordisk, a Danish company founded in 1923, is one of the global leaders in healthcare dedicated to addressing diabetes and chronic diseases. Headquartered just outside of Copenhagen, Novo Nordisk operates around 80 offices in over 160 countries, serving patients and healthcare professionals with the help of over 50.000 staff. The company has a rich history of pioneering research and innovation in the field of diabetes care, providing a range of pharmaceutical products and treatment solutions. Novo Nordisk is one of the largest companies in Denmark, and acts as a key player in the Danish economy together with companies such as Carlsberg and Maersk.

Novo Nordisk is renowned for its significant contributions in the field of diabetes treatment. With a strong focus on research and innovation, the company develops and provides a wide range of pharmaceutical products and therapies to help manage diabetes and improve patients' quality of life. Novo Nordisk's range of products for diabetes care includes insulin products, injectable and oral glucose-lowering medications, as well as devices for insulin administration. The company is committed to advancing diabetes care through ongoing research, development of new treatments, and educational initiatives for healthcare professionals and patients. Diabetes treatment is in huge demand worldwide, and other companies providing insulin for patients across the globe include companies like Eli Lilly and Sanofi.

Experts in chronic illness, Novo Nordisk is dedicated to addressing a range of health conditions beyond just diabetes. Their portfolio of products includes treatments for obesity, hemophilia, growth disorders, and rare diseases. By focusing on patient needs and utilizing their experience and scientific expertise, Novo Nordisk strives to provide the best possible solutions and care for patients who rely on medication in their day-to-day lives.